W15. Digital Health Startups Panel and Pitch – Securing Funding and Collaboration
TUESDAY, APRIL 21 | 12:30 - 3:30 PM
Pitch your digital health solution to VCs!
Are you a digital health startup ready to disrupt the status quo and leverage the shifting space of compute-intensive edge applications? We are looking for software, data integration, sensor companies, etc. working on innovative solutions for improved
capture, analysis, processing, transfer, and storage of digital health data. Accepted companies will have the opportunity to pitch their ideas to the venture capitalist panel. Please contact Hannah Loss at email@example.com for
To be eligible to participate, companies must be:
- Addressing an unmet digital health need
- Founded no earlier than 2014
- Actively seeking funding
TOPICS TO BE COVERED:
- Trends in digital health – why digital health matters
- What VCs look for in digital health companies, with input from VCs
- How to collaborate with pharma/tech companies when you are a startup
WHO SHOULD ATTEND:
Startups and anyone interested in ventures and digital health.
FEATURED DIGITAL HEALTH COMPANIES:
Ardy Arianpour, CEO & Co-Founder, Seqster
Additional companies to be announced.
VENTURE CAPITALIST PANEL:
Debbie Lin, PhD MPP, MSc Eng, Executive Director, Boehringer Ingelheim Venture Fund USA, Inc.
Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she
worked across various regions and divisions. She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West
Coast. She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka. In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and
Development as Director of Corporate Development. There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation. She led multi-country teams to set up the company’s first stroke
rehabilitation centers in Shanghai, China and in Lisbon, Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont
and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA. Debbie is a native Californian,
she loves sunshine, being around nature and the ocean, yoga and dogs.
Sean Cheng, PhD, Investment Manager, Philips Ventures
Sean is currently an Investment Manager at Philips Ventures, a portfolio of promising health tech companies including Babyscripts, Xealth, Mytonomy, as well as a fund-of-funds to fulfill the Philips Healthtech strategy. He is interested in early-stage
investment opportunities in digital health, medical devices and therapeutics.
Previously, Sean held positions at the Boston Consulting Group, the US FDA, and NASA. Sean also serves on the Board of Directors of The Professional Center for Child Development, Board of Advisors at the Johns Hopkins University, and the Advisory Council
of the World Economic Forum's Global Shapers Community. Sean holds a PhD in Engineering from the University of Cambridge in England, where he developed expertise in medical device design and optimization algorithms.
Millie Liu, Founder, Managing Partner, First Star Ventures
Millie Liu has focused her career on helping entrepreneurs with deep technology turn their ideas into great businesses with global reach.
She was previously at APT, an enterprise data analytics startup acquired by Mastercard for $600 million where she helped Fortune 50 clients such as Walmart and P&G make better strategic decisions leveraging data. She was also the co-founder of an
MIT startup working on unsupervised event detection, which later pivoted and became Infervision, an AI precision healthcare platform backed by Sequoia China. Millie is on the advisory board of MIT CSAIL (Computer Science and Artificial Intelligence
Lab). She holds a Master of Finance degree from MIT and B. in Mathematics from the University of Toronto.
Corey Centen, CEO and Co-Founder, Bodyport
Corey is the CEO and co-founder of Bodyport, a medical device company developing a novel remote cardiac monitoring system aimed at reducing hospitalizations through the early detection of changes in patient status. Prior to founding Bodyport, Corey was the co-founder and CEO at Atreo Medical, where he led the design of a proprietary sensor for measuring cardiopulmonary resuscitation (CPR) quality to help improve survival outcomes from cardiac arrest. He led the company from its inception through its acquisition to Medtronic. Following the acquisition, Corey joined Medtronic and led technology transfer and sensor development for the TrueCPR product. Corey's experience spans biomedical instrumentation and algorithms engineering. He holds 25 issued and pending patents, and his inventions have been featured in Popular Science and Time Magazine’s ‘Inventions of the Year’. He is originally from Ottawa, Canada and holds a degree in biomedical and electrical engineering from McMaster University.
Back to Workshops